Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Timo Vesikari, Aino Forstén, Dominique Boutriau, Véronique Bianco, Marie Van der Wielen & Jacqueline M. Miller. (2012) A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years. Human Vaccines & Immunotherapeutics 8:12, pages 1882-1891.
Read now
Read now
Kim S. Erlich & Blaise L. Congeni. (2012) Importance of circulating antibodies in protection against meningococcal disease. Human Vaccines & Immunotherapeutics 8:8, pages 1029-1035.
Read now
Read now
Markus Knuf, Yaela Baine, Véronique Bianco, Dominique Boutriau & Jacqueline M. Miller. (2012) Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Human Vaccines & Immunotherapeutics 8:7, pages 866-872.
Read now
Read now
Bernard Fritzell & Mark A Fletcher. (2011) Pneumococcal polysaccharide–protein (CRM197) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. Expert Review of Vaccines 10:3, pages 263-290.
Read now
Read now
Stephen I Pelton & Gregory P Gilmet. (2009) Expanding prevention of invasive meningococcal disease. Expert Review of Vaccines 8:6, pages 717-727.
Read now
Read now
Kwang Sik Kim. (2009) Treatment strategies for central nervous system infections. Expert Opinion on Pharmacotherapy 10:8, pages 1307-1317.
Read now
Read now
Ray Borrow & Jamie Findlow. (2009) Prevention of meningococcal serogroup C disease by NeisVac-C™. Expert Review of Vaccines 8:3, pages 265-279.
Read now
Read now
Sanford R Kimmel. (2008) Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease. Therapeutics and Clinical Risk Management 4:4, pages 739-745.
Read now
Read now
Guilherme Gonçalves. (2008) Herd immunity: recent uses in vaccine assessment. Expert Review of Vaccines 7:10, pages 1493-1506.
Read now
Read now
Articles from other publishers (38)
Jennifer L. Oliver, Christine Sadorge, Florence Boisnard, Matthew D. Snape, Richard Tomlinson, Rebecca Mann, Peter Rudd, Shyam Bhakthavalsala, Saul N. Faust, Paul T. Heath, Stephen M. Hughes, Ray Borrow, Stéphane Thomas & Adam Finn. (2020) Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. Vaccine 38:35, pages 5718-5725.
Crossref
Crossref
Philippe Lepage & Sophie Blumental. (2017) Specialty Grand Challenge In Pediatric Infectious Diseases. Frontiers in Pediatrics 5.
Crossref
Crossref
R A G da Silva, C P Churchward, A V Karlyshev, O Eleftheriadou, A K Snabaitis, M R Longman, A Ryan & R Griffin. (2017)
The role of apolipoprotein N-acyl transferase, Lnt, in the lipidation of factor H binding protein of
Neisseria meningitidis
strain MC58 and its potential as a drug target
. British Journal of Pharmacology 174:14, pages 2247-2260.
Crossref
Crossref
Nicola P. Klein, Yaela Baine, Devayani Kolhe, Carmen I. Baccarini, Jacqueline M. Miller & Marie Van der Wielen. (2016) Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. The Pediatric Infectious Disease Journal 35:6, pages 662-672.
Crossref
Crossref
Charissa Fay Corazon Borja-Tabora, Cecilia Montalban, Ziad A. Memish, Dominique Boutriau, Devayani Kolhe, Jacqueline M. Miller & Marie Van der Wielen. (2015) Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC Infectious Diseases 15:1.
Crossref
Crossref
Robert Booy, Terry Nolan, Graham Reynolds, Peter Richmond, Michael Nissen, Helen Marshall, Tanya Stoney, Marie Van Der Wielen, Devayani Kolhe & Jacqueline M. Miller. (2015) Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers. Pediatric Infectious Disease Journal 34:12, pages 1379-1384.
Crossref
Crossref
Milagritos D. Tapia, Helen Findlow, Olubukola T. Idoko, Marie-Pierre Preziosi, Prasad S. Kulkarni, Godwin C. Enwere, Cheryl Elie, Varsha Parulekar, Samba O. Sow, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Adebayo K. Akinsola, Richard A. Adegbola, Beate Kampmann, Julie Chaumont, Lionel Martellet, Elisa Marchetti, Simonetta Viviani, Yuxiao Tang, Brian D. Plikaytis, F. Marc LaForce, George Carlone & Ray Borrow. (2015) Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age. Clinical Infectious Diseases 61:suppl_5, pages S514-S520.
Crossref
Crossref
Daniel Holme, Helen Findlow, Samba O. Sow, Olubukola T. Idoko, Marie-Pierre Preziosi, George Carlone, Brian D. Plikaytis & Ray Borrow. (2015) Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination. Clinical Infectious Diseases 61:suppl_5, pages S563-S569.
Crossref
Crossref
Magdalena K. Bielecka, Nathalie Devos, Mélanie Gilbert, Miao-Chiu Hung, Vincent Weynants, John E. Heckels & Myron Christodoulides. (2015) Recombinant Protein Truncation Strategy for Inducing Bactericidal Antibodies to the Macrophage Infectivity Potentiator Protein of Neisseria meningitidis and Circumventing Potential Cross-Reactivity with Human FK506-Binding Proteins. Infection and Immunity 83:2, pages 730-742.
Crossref
Crossref
Kelly Townsend, Shamez N. Ladhani, Helen Findlow & Ray Borrow. (2014) Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection. Vaccine 32:43, pages 5650-5656.
Crossref
Crossref
Sigurveig Th. Sigurdardottir, Kimberly J. Center, Katrin Davidsdottir, Vilhjalmur A. Arason, Bjorn Hjalmarsson, Ragnheidur Elisdottir, Gunnhildur Ingolfsdottir, Robert Northington, Daniel A. Scott & Ingileif Jonsdottir. (2014) Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. Vaccine 32:3, pages 417-424.
Crossref
Crossref
Charissa Borja-Tabora, Cecilia Montalban, Ziad A Memish, Marie Van der Wielen, Veronique Bianco, Dominique Boutriau & Jacqueline Miller. (2013) Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infectious Diseases 13:1.
Crossref
Crossref
Socorro Lupisan, Kriengsak Limkittikul, Nestor Sosa, Pornthep Chanthavanich, Véronique Bianco, Yaela Baine, Marie Van der Wielen & Jacqueline M. Miller. (2013)
Meningococcal Polysaccharide A
O
-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years
. Clinical and Vaccine Immunology 20:10, pages 1499-1507.
Crossref
Crossref
Markus Knuf, Olivier Romain, Klaus Kindler, Uta Walther, Phu-My Tran, Heidemarie Pankow-Culot, Thomas Fischbach, Dorothee Kieninger-Baum, Véronique Bianco, Yaela Baine & Jacqueline Miller. (2013) Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study. European Journal of Pediatrics 172:5, pages 601-612.
Crossref
Crossref
Tone Tønjum, Petter Brandtzæg & Birgitta Henriques-Normark. 2013. The Prokaryotes. The Prokaryotes
401
427
.
Daniela Vinhas Bertolini, Luciana Scarlazzari Costa, Inneke Marie van der Heijden, Helena Keiko Sato & Heloísa Helena de Sousa Marques. (2012) Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults. Vaccine 30:37, pages 5482-5486.
Crossref
Crossref
Lucia H. Lee & Milan S. Blake. (2012)
Effect of Increased CRM
197
Carrier Protein Dose on Meningococcal C Bactericidal Antibody Response
. Clinical and Vaccine Immunology 19:4, pages 551-556.
Crossref
Crossref
Lars Østergaard, Sven-Arne Silfverdal, Johan Berglund, Carl-Erik Flodmark, Christina West, Veronique Bianco, Yaela Baine & Jacqueline M. Miller. (2012) A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial. Vaccine 30:4, pages 774-783.
Crossref
Crossref
Miao-Chiu Hung, Omar Salim, Jeannette N. Williams, John E. Heckels & Myron Christodoulides. (2011) The Neisseria meningitidis Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate. Infection and Immunity 79:9, pages 3784-3791.
Crossref
Crossref
Manuela Zlamy, Johannes Elias, Ulrich Vogel, Matthias Frosch, Verena Jeller, Gerard Cortina, Therese Jungraithmayr & Martina Prelog. (2011) Immunogenicity of conjugate Meningococcus C vaccine in pediatric solid organ transplant recipients. Vaccine 29:37, pages 6163-6166.
Crossref
Crossref
Ulrich Vogel & Heike Claus. (2010)
Vaccine development against
Neisseria meningitidis
. Microbial Biotechnology 4:1, pages 20-31.
Crossref
Crossref
Elena Chiappini, Elisabetta Venturini, Francesca Bonsignori, Luisa Galli & Maurizio De Martino. (2010) Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatrica 99:11, pages 1609-1614.
Crossref
Crossref
Keith S. ReisingerSteven Black & Jeffrey J. Stoddard. (2010) Optimizing Protection Against Meningococcal Disease. Clinical Pediatrics 49:6, pages 586-597.
Crossref
Crossref
Alfonso Carmona, Mariano Miranda, Francisco Barrio, Ana De Vicente, Josep Mares, Eulalia Muñoz, Javier Diez-Delgado, Angeles Alonso, Francisco Giménez-Sánchez, José Merino, Pilar García-Corbeira, Gudrun Maechler & Dominique Boutriau. (2010) REACTOGENICITY AND IMMUNOGENICITY OF COMBINED HAEMOPHILUS INFLUENZAE TYPE B-MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE BOOSTER DOSE COADMINISTERED WITH MEASLES, MUMPS, AND RUBELLA VACCINEHIB-MENC-TT BOOSTER WITH ROUTINE MMR VACCINE. Pediatric Infectious Disease Journal 29:3, pages 269-271.
Crossref
Crossref
Peng-jun Lu, Nidhi Jain & Amanda C. Cohn. (2010) Meningococcal conjugate vaccination among adolescents aged 13–17 years, United States, 2007. Vaccine 28:11, pages 2350-2355.
Crossref
Crossref
Kwang Sik Kim. (2010) Acute bacterial meningitis in infants and children. The Lancet Infectious Diseases 10:1, pages 32-42.
Crossref
Crossref
Craig P. White & Jeff Scott. (2010) Meningococcal Serogroup C Conjugate Vaccination in Canada: How Far Have We Progressed? How Far Do We Have to Go?. Canadian Journal of Public Health 101:1, pages 12-14.
Crossref
Crossref
Nicholas Kitchin, Joanna Southern, Rhonwen Morris, Ray Borrow, Anne Fiquet, Florence Boisnard, Stéphane Thomas & Elizabeth Miller. (2009) Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 27:37, pages 5096-5102.
Crossref
Crossref
Flora Castellino, Grazia Galli, Giuseppe Del Giudice & Rino Rappuoli. (2009) Generating memory with vaccination. European Journal of Immunology 39:8, pages 2100-2105.
Crossref
Crossref
Ray Borrow. (2009) Meningococcal disease and prevention at the Hajj. Travel Medicine and Infectious Disease 7:4, pages 219-225.
Crossref
Crossref
C. Levy, F. de La Rocque & R. Cohen. (2009) Actualisation de l’épidémiologie des méningites bactériennes de l’enfant en France. Médecine et Maladies Infectieuses 39:7-8, pages 419-431.
Crossref
Crossref
C. Levy, M.-K. Taha, C. Weill Olivier, B. Quinet, A. Lécuyer, J.-M. Alonso, R. Cohen & E. Bingen. (2008) Caractéristiques des méningites à méningocoque de l'enfant en France. Archives de Pédiatrie 15, pages S105-S110.
Crossref
Crossref
Caroline L. Trotter, Ray Borrow, Jamie Findlow, Ann Holland, Sarah Frankland, Nick J. Andrews & Elizabeth Miller. (2008) Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era. Clinical and Vaccine Immunology 15:11, pages 1694-1698.
Crossref
Crossref
Kwang Sik Kim. (2008) Mechanisms of microbial traversal of the blood–brain barrier. Nature Reviews Microbiology 6:8, pages 625-634.
Crossref
Crossref
Juan C. Tejedor, Manuel Moro, José Manuel Merino, José Antonio Gómez-Campderá, Manuel García-del-Rio, Antonio Jurado, Francisco Javier Díez-Delgado, Félix Omeñaca, José García-Sicilia, Jesús Ruiz-Contreras, Ana Martin-Ancel, Joan Roca, Reyes Boceta, Pilar García-Corbeira, Gudrun Maechler & Dominique Boutriau. (2008) Immunogenicity and Reactogenicity of a Booster Dose of a Novel Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine Given to Toddlers of 13–14 Months of Age With Antibody Persistence Up to 31 Months of Age. Pediatric Infectious Disease Journal 27:7, pages 579-588.
Crossref
Crossref
William P. Hausdorff, Angela B. Brueggemann, Jill G. Hackell, J. Anthony & G. Scott. 2008. Pneumococcal Vaccines. Pneumococcal Vaccines
139
160
.
José Antonio Navarro-Alonso. (2008) Vacunas antimeningocócicas. Enfermedades Infecciosas y Microbiología Clínica 26, pages 20-28.
Crossref
Crossref
Alexander Doroshenko & Scott A Halperin. (2007) Vaccination: the importance of herd immunity. Pediatric Health 1:1, pages 35-42.
Crossref
Crossref